Increased Hepato-Splanchnic Vasoconstriction in Diabetics during Regular Hemodialysis by Ribitsch, Werner et al.
  
 University of Groningen
Increased Hepato-Splanchnic Vasoconstriction in Diabetics during Regular Hemodialysis
Ribitsch, Werner; Schneditz, Daniel; Franssen, Casper F. M.; Schilcher, Gernot; Stadlbauer,





IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
it. Please check the document version below.
Document Version
Publisher's PDF, also known as Version of record
Publication date:
2015
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):
Ribitsch, W., Schneditz, D., Franssen, C. F. M., Schilcher, G., Stadlbauer, V., Horina, J. H., & Rosenkranz,
A. R. (2015). Increased Hepato-Splanchnic Vasoconstriction in Diabetics during Regular Hemodialysis.
PLoS ONE, 10(12), [e0145411]. https://doi.org/10.1371/journal.pone.0145411
Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the
author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the




Vasoconstriction in Diabetics during Regular
Hemodialysis
Werner Ribitsch1*, Daniel Schneditz2, Casper F. M. Franssen3, Gernot Schilcher1,
Vanessa Stadlbauer4, Jörg H. Horina1, Alexander R. Rosenkranz1
1 Department of Internal Medicine, Clinical Division of Nephrology, Medical University of Graz, Graz, Austria,
2 Institute of Physiology, Medical University of Graz, Graz, Austria, 3 Department of Internal Medicine,
Division of Nephrology, University Medical Center Groningen, Groningen, The Netherlands, 4 Department of





Ultrafiltration (UF) of excess fluid activates numerous compensatory mechanisms during
hemodialysis (HD). The increase of both total peripheral and splanchnic vascular resistance
is considered essential in maintaining hemodynamic stability. The aim of this study was to
evaluate the extent of UF-induced changes in hepato-splanchnic blood flow and resistance
in a group of maintenance HD patients during regular dialysis.
Design, Setting, Participants, & Measurements
Hepato-splanchnic flow resistance index (RI) and hepato-splanchnic perfusion index (QI)
were measured in 12 chronic HD patients using a modified, non-invasive Indocyaningreen
(ICG) dilution method. During a midweek dialysis session we determined RI, QI, ICG disap-
pearance rate (kICG), plasma volume (Vp), hematocrit (Hct), mean arterial blood pressure
(MAP) and heart rate (HR) at four times in hourly intervals (t1 to t4). Dialysis settings were
standardized and all patient studies were done in duplicate.
Results
In the whole study group mean UF volume was 1.86 ± 0.46 L, Vp dropped from 3.65 ±
0.77L at t1 to 3.40 ± 0.78L at t4, and all patients remained hemodynamically stable. In all
patients RI significantly increased from 12.40 ± 4.21 mmHgsm2/mL at t1 to 14.94 ± 6.36
mmHgsm2/mL at t4 while QI significantly decreased from 0.61 ± 0.22 at t1 to 0.52 ± 0.20
L/min/m2 at t4, indicating active vasoconstriction. In diabetic subjects, however, RI was
significantly larger than in non-diabetics at all time points. QI was lower in diabetic
subjects.
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Conclusions
In chronic HD-patients hepato-splanchnic blood flow substantially decreases during moder-
ate UF as a result of an active splanchnic vasoconstriction. Our data indicate that diabetic
HD-patients are particularly prone to splanchnic ischemia and might therefore have an
increased risk for bacterial translocation, endotoxemia and systemic inflammation.
Introduction
Ultrafiltration (UF) induced hypovolemia activates a variety of compensatory mechanisms to
maintain hemodynamic stability during hemodialysis (HD). However, failure of the hemody-
namic response to counterbalance central hypovolemia and inadequate plasma refilling may
lead to intradialytic hypotension, an acute complication occurring in 15 to 30% of HD treat-
ments [1]. In hypovolemic states an active vasoconstriction of the splanchnic vascular bed
increasing both vascular resistance and venous return is considered fundamental to maintain
hemodynamic stability [2]. Results from early studies showing a decrease of splanchnic blood
flow during HD-treatment are in support of this important compensatory response to hypovo-
lemia [3] [4] [5]. However, it is believed that a pronounced splanchnic hypoperfusion for pro-
longed periods of time such as during HD and UF might weaken the gut barrier thereby
facilitating bacterial translocation, endotoxemia, and systemic inflammation [6] [7] [8]. The
adverse consequence of splanchnic hypoperfusion has been termed “gut stunning” [6] in anal-
ogy to myocardial stunning observed during HD [9] [10]. Although undisputed in essence, the
details are incompletely understood and concise information about the impact of ultrafiltration
on hepato-splanchnic vascular resistance and splanchnic blood flow is sparse. Even though a
few early studies have addressed some of these questions [3] [4] [5], it is difficult to transfer the
results of these studies to a chronic HD-population in a clinical routine setting.
The aim of our study therefore was to investigate the magnitude of ultrafiltration-induced
changes in hepato-splanchnic resistance and perfusion in a group of stable end stage kidney
disease (ESKD) patients during regular dialysis treatments.
Material and Methods
Patients
The study was done in accordance with the Declaration of Helsinki at the Clinical Division of
Nephrology, Medical University of Graz, Austria. All patients gave their written informed con-
sent prior to this study, which was approved by the Institutional Review Board of the Medical
University of Graz (registration number 23–056 ex 10/11). Subjects with abnormal liver func-
tion tests or other hepatic disease were excluded. Patients were studied during their regular
midweek treatment with either HD or online hemodiafiltration (HDF) delivered in post-dilu-
tion mode. Patients were studied in supine body position and were fasting prior to and during
the study period to rule out hemodynamic perturbances of the splanchnic region caused by
food intake [11] [12]. The ultrafiltration rate was constant throughout dialysis, the dialysate
temperature was set at 37°C, and the dialysate sodium prescription was individualized to
match the patient’s plasma sodium concentration as measured at dialysis start. Studies were
repeated on the same weekday of the following week.
Study protocol
Hepato-splanchnic perfusion (Q) was measured using a modified indocyanine green (ICG)
dilution method as described elsewhere [13] [14]. ICG is a classic dye used for hemodynamic
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measurements. In plasma ICG binds to albumin and its dilution has been used to examine the
magnitude as well as the changes in plasma volume during dialysis as it is not removed from
the circulation by the dialyzer [15]. ICG is exclusively eliminated by the liver, also during dialy-
sis. With normal liver function the half-life is about 3 to 4 min so that all dye is removed from
the circulation within 15 to 20 min allowing for multiple measurements during the same appli-
cation. Moreover, the extraction from blood passing the liver sinusoids is almost 100% with
normal liver function so that the clearance of ICG refers to total hepato-splanchnic blood flow
(Q). Four mL of a 5 mg/mL solution of ICG (ICG-PULSION1, PULSIONMedical Systems,
Munich, Germany) were injected into the venous blood line of the extracorporeal circulation.
The first bolus at time t1 (baseline) was delivered within 15 min after treatment start and three
subsequent boli were administered in hourly intervals at times t2, t3, and t4. ICG-concentra-
tions were continuously and non-invasively measured by optical means with a sampling period
of 20 s (CLI, CritLine1 Instrument, Fresenius Medical Care, Utah, USA). Distribution volume
and clearance of ICG were derived from analysis of ICG dilution curves assuming single-pool
kinetics at the four measuring points t1 to t4 during HD as described elsewhere [14]. The blood
disappearance rate (ICG-disappearance rate, the normal range varying between 18–25%/min)
was determined from the slope of the elimination curve. Hematocrit (Hct) and plasma volume
(Vp) were derived from the CLI readings immediately prior to each ICG-injection at times t1
through t4.
Hemodynamics were assessed by mean arterial pressure (MAP) and heart rate (HR).
Hepato-splanchnic resistance (R) was estimated from the ratio of mean arterial pressure to
hepato-splanchnic blood flow (Q) assuming negligible hepatic venous pressure. For practical
reasons resistance is given in non-SI peripheral resistance units (PRU, mmHg.s/mL).
To account for differences in body size, hepato-splanchnic blood flow and resistance were
normalized for body surface area (A) to obtain hepato-splanchnic flow index (QI = Q/A, in L/
min/m2) and hepato-splanchnic resistance index (RI = RA, in PRU.m2), respectively. Body
surface (A) was calculated according to the Du Bois formula [16].
Statistical Analyses
Hemodynamic data obtained in subsequent treatments were averaged to account for repeated
measurements in the same subject Results are presented as the mean value ± SD or the median
and interquartile range. Normal distribution of the data was verified by the Kolmogorov-Smir-
nov test. Statistical methods used were two-sample t-test for comparison of means and single
factor variance analyses with repeated measurement for analyses of temporal changes. The
reproducibility of repeated individual measurements was evaluated by Pearson’s correlation
coefficient r and Wilcoxon signed rank test. A p< 0.05 was considered significant. Statistical
calculations were done with SPSS, Version 20.0 for Windows (SPSS Inc., Chicago, IL, USA).
Results
We studied 12 (6 female) chronic HD-patients in whom ESKD was due to diabetic nephropa-
thy (2 type-I and 1 type-II diabetes mellitus, respectively) (three), focal segmental glomerulo-
sclerosis (one), bilateral nephrectomy due to urothelcarcinoma (one), gestosis (one),
hemolytic-uremic syndrome (one), unknown (two), interstitial nephritis (one), hypertensive
glomerulosclerosis (one), and amyloidosis secondary to Crohn´s Disesase with ankylosing
spondylitis (one). As Crohn’s Disease may affect hepato-splanchnic blood flow depending on
disease activity [17, 18], a closer look at the patient history revealed remission as quantified by
a Harvey Bradshaw Index Score of 3 (a score< 5 indicating remission, [19]) with leukocyte
counts and C-reactive protein levels within the normal range. Relevant extrarenal
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manifestations of amyloidosis were excluded by echocardiogram and colonic biopsy which
were both negative for myocardial infiltrations and colonic amyloid deposits. Therefore, this
non-diabetic patient was included in the study. The most frequent comorbidities were hyper-
tension (ten), coronary heart disease (four), peripheral artery disease (three) secondary hyper-
parathyreoidism (eleven) and renal anemia (twelve). Five (41.7%) patients were diabetics; the
mean ultrafiltration volume was 1.86 ± 0.4 6L (Table 1). Treatments were completed without
hypotension and without gastro-intestinal symptoms. Individual measurements obtained on
separate study days were highly correlated with a negligible variation thus revealing a good
reproducibility of the measurements. For example, flow index measurements repeated in sub-
sequent weeks were highly correlated (r = 0.94, p<0.0001) and not different between studies
done in the same patient. Hemodynamic variables measured in subsequent treatments done in
the same patient were therefore averaged and used for further analysis. As expected, hematocrit
increased from 35.13 ± 2.13 at t1 to 36.72 ± 2.01% at t4 (p = 0.003), paralleled by a decrease in
plasma volume from 3.65 ± 0.77 to 3.40 ± 0.78 L (p = 0.008). Heart rate and mean arterial pres-
sure did not change during the study period. All study subjects exhibited an ICG-PDR of larger
than 10% (Table 2), a prerequisite for a valid estimate of hepato-splachnic blood flow (Q) by
ICG-Clearance [4]. In the study population as a whole, hepato-splanchnic blood flow index
(QI) dropped from 0.61 ± 0.22 at t1 to 0.52 ± 0.20 L/min/m
2 at t4 (p = 0.003, Table 2), corrobo-
rated by a decrement of ICG disappearance rate from 19.3 ± 6.2 to 18.2 ± 5.2%/min
(p = 0.001). Hepato-splanchnic vascular resistance index (RI) increased from 12.40 ± 4.21 at t1
to 14.94 ± 6.36 PRUm² at t4 (p< 0.001, Table 2), corresponding to a relative increase by 19.2%
(p = 0.01, Table 3). There was no correlation between ultrafiltration rate and either R or QI
(data not shown). The comparison of flow to resistance confirmed the expected hyperbolic
relationship for constant mean arterial pressure with flow decreasing as resistance increased
(Fig 1, top panel). Transformation of resistance (RI) into conductance (1/RI) provided the
expected linear relationship with flow increasing as conductance increased (Fig 1, bottom
panel). Notice that diabetic patients are clustered at the high resistance, low conductance end
of these graphs.
Table 1. Patient and treatment characteristics.
All (n = 12) Diabetics (n = 5) Non-Diabetics (n = 7) p
Female (n) 6 4 2
Age (y) 53 (32–80) 54 (47–80) 53 (32–71) 0.19
M (kg) 71.9 ± 14.5 63.4 ± 10.3 78.0 ± 14.5 0.08
Height (cm) 170.3 ± 8.9 165.2 ± 10.0 174.0 ± 6.6 0.09
BMI (kg/m2) 24.7 ± 3.9 23.1 ± 2.4 25.7 ± 4.6 0.27
A (m2) 1.8 ± 0.2 1.7 ± 0.2 1.9 ± 0.2 0.06
Dialysis vintage (mo) 82.0 ± 60.5 77.8 ± 65.8 85.0± 61.5 0.85
Vuf (L) 1.86 ± 0.46 1.85 ± 0.53 1.87 ± 0.44 0.95
Na+d (mmol/L) 137.9 ± 2.6 138.3 ± 1.6 137.6 ± 3.3 0.66
Qb (mL/min) 288 ± 20 278 ± 18 294 ± 19 0.17
HDF (n) 10 3 7
HD (n) 2 2 0
ACE-Inhibitor 1 1 0
ß-blocker 5 2 3
n: number of subjects; p: probability; M: body mass at dry weight; BMI: body mass index; A: body surface area; Vuf: ultraﬁltration volume; Na
+
d dialysate
sodium concentration; Qb: extracorporeal blood ﬂow; HDF: hemodiaﬁltration: HD: hemodialysis; ACE: angiotensin-converting-enzyme
doi:10.1371/journal.pone.0145411.t001
Hepato-Splanchnic Vascular Resistance during Hemodialysis
PLOS ONE | DOI:10.1371/journal.pone.0145411 December 29, 2015 4 / 14
Table 2. Hemodynamic variables at time points t1 through t4.
All (n = 12) Diabetics (n = 5) Non-Diabetics (n = 7) p+
MAP (mmHg)
t1 114 .2 ± 16.8 116.0 ± 3.4 112.9 ± 22.4 0.77
t2 110.4 ± 16.9 114.9 ± 9.2 107.2 ± 20.9 0.46
t3 109.7 ± 23.1 115.6 ± 26.4 105.5 ± 21.5 0.48
t4 111.7 ± 22.4 116.8 ± 18.9 108.1 ± 25.4 0.53
p* 0.71 0.99 0.14
HR (1/min)
t1 70.5 ± 11.4 65.5 ± 14.5 74.0 ± 7.9 0.22
t2 69.6 ± 12.9 64.7 ± 14.7 73.2 ± 11.3 0.28
t3 69.3 ± 13.3 64.0 ± 18.7 73.1 ± 7.3 0.26
t4 72.1 ± 15.2 66.2 ± 22.1 76.3 ± 6.7 0.28
p* 0.82 0.89 0.49
Hct (%)
t1 35.13 ± 2.13 35.73 ± 2.51 34.70 ± 1.90 0.44
t2 35.67 ± 2.18 36.29 ± 2.70 35.22 ± 1.81 0.43
t3 35.62 ± 1.83 35.52 ± 2.40 35.69 ± 1.51 0.88
t4 36.72 ± 2.01 37.57 ± 2.38 36.11 ± 1.62 0.23
p* 0.003 0.17 < 0.001
Vp (L)
t1 3.65 ± 0.77 3.03 ± 0.82 4.09 ± 0.29 0.009
t2 3.48 ± 0.81 2.99 ± 0.85 3.84 ± 0.62 0.07
t3 3.55 ± 0.83 2.96 ± 0.85 3.98 ± 0.52 0.03
t4 3.40 ± 0.78 2.86 ± 0.82 3.79 ± 0.49 0.03
p* 0.008 0.03 0.03
QI (L/min/m2)
t1 0.61 ± 0.22 0.47 ± 0.13 0.72 ± 0.23 0.06
t2 0.56 ± 0.19 0.43 ± 0.15 0.66 ± 0.18 0.04
t3 0.54 ± 0.22 0.39 ± 0.14 0.64 ± 0.21 0.04
t4 0.52 ± 0.20 0.39 ± 0.15 0.61 ± 0.19 0.07
p* 0.003 0.001 p = 0.07
ICG-DR (%/min)
t1 19.3 ± 6.2 16.2 ± 4.2 21.5 ± 6.6 0.15
t2 18.8 ± 5.8 15.8 ± 4.2 20.9 ± 6.0 0.14
t3 18.3 ± 5.5 15.7 ± 4.2 20.2 ± 5.8 0.17
t4 18.2 ± 5.2 15.8 ± 4.5 19.9 ± 5.3 0.19
p* 0.001 0.29 0.002
RI (mmHgsm2/mL)
t1 12.40 ± 4.21 15.71 ± 4.23 10.03 ± 2.21 0.01
t2 13.30 ± 5.43 17.64 ± 5.85 10.19 ± 2.06 0.01
t3 14.27 ± 6.18 19.65 ± 5.99 10.43 ± 2.19 0.004
t4 14.94 ± 6.36 20.29 ± 6.46 11.11 ± 2.29 0.005
p* 0.001 0.01 0.18
n: number of subjects; MAP: mean arterial pressure; HR: heart rate: Hct: hematocrit: Vp: plasma volume: QI: hepato-splanchnic blood ﬂow index: ICG-DR,
Indocyanine green disappearance rate: RI, hepato-splanchnic vascular resistance index; p*: probability for single factor variance analyses with repeated
measurement; p+: probability for two sample t-test for comparison between diabetics and non-diabetics
doi:10.1371/journal.pone.0145411.t002
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Diabetic and non-diabetic subgroups
Diabetics and non-diabetics were comparable with respect to baseline anthropometric charac-
teristics, dialysis vintage and ultrafiltration volumes (Table 1). Although both groups remained
hemodynamically stable throughout the study period, hepato-splanchnic blood flow was sig-
nificantly lower in diabetics than in the non-diabetic cohort at t2 and t3, barely missing signifi-
cance at t1 and t4 (Table 2, Fig 2, top panel). By contrast, both groups did not differ with regard
to their ICG disappearance rate. The reduced hepato-splanchnic blood flow index in the dia-
betic subgroup was related to a significantly greater hepato-splanchnic vascular resistance
index (RI) in this cohort (Table 2, Fig 2, bottom panel). The separation of groups is also clearly
seen in the perfusion vs. resistance or conductance plots. Contrary to the disparities between
absolute values of QI and RI at the different time points, we observed no significant difference
in the relative changes of QI and RI between the two groups during HD (Table 3). Original
data are provided in the supplementary file (S1 Table).
Discussion
The main observation of this study is that hepato-splanchnic resistance was about 30% higher
in diabetic compared to non-diabetic patients already at the beginning of measurements, 15
min into dialysis, corresponding to a hepato-splanchnic blood flow that was only two thirds of
that in non-diabetic patients. Furthermore, to maintain a stable arterial blood pressure during
ultrafiltration-induced decline in plasma volume hepato-splanchnic resistance increased dur-
ing HD in non-diabetic as well as in diabetic patients. Interestingly, this increase was much
more pronounced in diabetic subjects compared to non-diabetic subjects.
In our study population arterial pressure and heart rate remained unchanged throughout
dialysis in spite of significant hemoconcentration and plasma volume reduction. These obser-
vations are akin with previous findings regarding hepato-splanchnic blood flow [4] [20]. The
splanchnic vascular bed is characterized by high vascular capacitance and compliance and
plays an important role to compensate for a fall in blood volume, venous return, central venous
pressure, cardiac output, and arterial blood pressure. During ultrafiltration fluid is first
removed from the blood volume and then partially refilled from the interstitial space [21]. The
initial removal is primarily from the compliant venous part of the circulation thereby causing a
Table 3. Relative perfusion and resistance changes.
All (n = 12) Diabetes (n = 5) Non Diabetes (n = 7) p+
ΔQI (%)
t2 -7.7 ± 8.1 -9.6 ± 7.5 -6.4 ± 8.8 0.52
t3 -12.0 ± 11.3 -15.2 ± 10.7 -9.7 ± 11.9 0.44
t4 -15.1 ± 10.5 -16.8 ± 13.7 -13.9 ± 8.5 0.67
p* 0.11 0.08 0.38
ΔRI (%)
t2 6.1 ± 11.9 11.2 ± 13.2 2.5 ± 10.3 0.22
t3 13.9 ± 20.9 26.3 ± 23.2 5.1 ± 14.9 0.08
t4 19.2 ± 18.8 29.6 ± 21.3 11.8 ± 13.9 0.11
p* 0.01 0.02 0.29
ΔQI: change of hepato-splanchnic blood ﬂow index at times t2, t3, and t4 relative to baseline at t1; ΔRI: change of hepato-splanchnic vascular resistance
index at times t2, t3, and t4 relative to baseline at t1; p*: probability for single factor variance analyses with repeated measurement; p
+: probability for two-
sample t-test for comparison between diabetics and non-diabetics
doi:10.1371/journal.pone.0145411.t003
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Fig 1. Hepato-splanchnic perfusion and resistance. Splanchnic perfusion index (QI) as function of
hepato-splanchnic resistance index (RI) (top panel) and hepato-splachnic vascular conductance (bottom
panel), respectively, during hemodialysis, in diabetic (red symbols) and non-diabetic (green symbols)
subjects. Broken lines indicate the best fit ofQI to RI (top panel, y = 6.71/x, r2 = 0.77) and 1/RI (bottom panel,
y = 0.02+6.54x, r2 = 0.77), respectively.
doi:10.1371/journal.pone.0145411.g001
Hepato-Splanchnic Vascular Resistance during Hemodialysis
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Fig 2. Time course of hepato-splanchnic hemodynamics. Time course of splanchnic vascular resistance
index (RI) (top panel) and hepato-splanchnic perfusion index (QI) (bottom panel) measured at times t1
through t4 during dialysis in diabetic (red symbols) and non-diabetic (green symbols) subjects. Symbols
represent average values ± standard deviations of duplicate measurements obtained in treatments separated
by one week. For clarity, symbols for diabetics and non-diabetics are placed with a small left or right offset
from the actual measuring times.
doi:10.1371/journal.pone.0145411.g002
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small decrease in venous pressures [22]. The resulting drop in central venous pressure will
therefore also tend to lower hepatic venous pressure. As central venous or hepatic venous pres-
sures were not measured in this study, the true arterio-venous pressure drop may have been
underestimated, resulting in a small underestimation of hepato-splanchnic resistance, if at all.
Therefore, the increase in hepato-splanchnic resistance calculated in this study represents a
conservative estimate given the uncertainties of true hepatic venous pressure changes.
The hemodynamic effects of ultrafiltration in hemodialysis have been reviewed elsewhere
[23]. Briefly, the decrease in venous pressure is assumed to reduce the ventricular preload
thereby reducing cardiac output and arterial pressures. This fall will then be compensated by
the baroreflex mechanism through central and peripheral control actions. The resulting
increase in peripheral resistance not only compensates for the decrease in arterial pressures but
also reduces the downstream distending pressures in compliant vascular beds such as the
hepato-splanchnic circulation, thereby shifting blood to central parts of the circulation com-
pensating for the initial decrease in central venous pressure and right atrial pressure (Fig 3).
This volume shift from a compliant vascular bed is also known as DeJager-Krogh effect [24]. In
our study the effect of ultrafiltration on splanchnic vasoconstriction is documented by a clear
reduction in ICG clearance. Our data indicate that hemodynamic stability is achieved at the
expense of a significantly reduced hepato-splanchnic perfusion. It is possible that a decrease of
hepato-splanchnic perfusion causes critical intestinal ischemia, especially during 4 hours of
HD and ultrafiltration although we cannot provide direct evidence for this phenomenon in our
study. Moreover, it is currently not possible to predict at what level of hepato-splanchnic vaso-
constriction a critical intestinal ischemia is likely to occur. However, diabetic patients starting
Fig 3. Scheme of hepato-splanchinc contribution for hemodynamic stability. Splanchnic
vasoconstriction reduces arterial inflow (black arrows) thereby lowering downstream distending pressures
and mobilizing blood volume (white arrows) sequestered in the compliant splanchnic vasculature. At the
same time reduced portal vein flow draining form splanchnic vascular beds (purple) causes a compensatory
increase (red arrow) in the separate hepatic arterial blood flow (red) because of compensatory vasodilation in
Mall´s space.
doi:10.1371/journal.pone.0145411.g003
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with a low perfusion seem to be at special risk. In this scenario, however, the liver itself is pro-
tected against hypoperfusion because of its dual blood supply and the hepatic-arterial buffer
response (HABR) [25] and a critical hepatic ischemia therefore appears to be less likely. The
hepato-splanchinc flow measured in this study represents the sum of both portal venous and
hepatic arterial inflows, and it is therefore not possible to allocate the overall reduction in
hepato-splanchnic blood flow to a specific source of the dual blood supply (Fig 3). Moreover,
because of hepatic-arterial buffer response intestinal perfusion might be reduced to a much
larger extent than total hepato-splanchnic blood flow. As a consequence, bacterial transloca-
tion, endotoxemia, and systemic inflammation might develop as a result of an ischemic gut
barrier during HD [5] [6] [26]. On the other hand, the ischemic splanchnic vascular bed may
act as a culprit of intradialytic hypotension by itself. It has been proposed that the ischemic gut
is an important source of adenosine, a purine nucleoside with vasodilating and cardiodepres-
sant properties, rapidly leading to profound intradialytic hypotension [27] [28].
The underperfusion of the hepato-splanchnic vascular bed especially in diabetics is not easy
to explain but it is in line with the occurrence of myocardial stunning observed shortly after
starting HD [10] [29]. Since baseline measurements were obtained after having established the
extracorporeal circulation the effect could be due to the mode of connecting the patient to the
extracorporeal circulation where only part of the priming volume is infused whereas about 100
to 150 mL of priming volume are discarded leading to an abrupt blood volume drop of 2 to 3%.
Diabetic patients could be more susceptible to this effect. The low perfusion and the high resis-
tance of the splanchnic region measured already at treatment start indicate a reduced range to
further increase splanchnic vascular resistance and compensate for UF-induced hypovolemia.
So far only a few studies addressed the impact of ultrafiltration on hepato-splanchnic resis-
tance and blood flow during HD. In an early study the splanchnic content of 99mTc-labeled
erythrocytes decreased by 10% with accelerated ultrafiltration of 3.7 L during 2 h [3]. However,
a change in volume cannot directly be translated into the same change in perfusion. A different
group reported a 22% decrease of hepato-splanchnic blood flow during dialysis in acute kidney
disease patients using constant ICG infusion given an UF-volume of 2 L [4]. The discrepancy
between these studies and our data can be explained by different study settings such as includ-
ing a heterogeneous ICU-cohort with acute renal failure in the latter study.
Our study encourages the assumption that diabetic dialysis patients might be particularly
prone to critical splanchnic ischemia during UF. Interestingly, we did not observe any differ-
ences in the relative changes of hepato-splanchnic blood flow or hepato-splanchnic resistance
between both groups. This suggests that vascular reactivity was maintained in diabetics. We
can only speculate about the mediators of splanchnic vasoconstriction leading to the marked
increase in vascular resistance from the onset of dialysis observed in our diabetic patients.
Severe systemic atherosclerosis inherent to the diabetic HD-population might play an impor-
tant role. However, diabetics represent only a small proportion of patients with chronic mesen-
teric ischemia in the general population [30], suggesting that other mechanisms are likely to be
involved.
Elevated catecholamine levels capable of increasing the vascular tone in the splanchnic cir-
culation are frequently found among diabetic ESKD-patients with diabetic neuropathy [31]
[32] [33]. Another possible trigger of splanchnic vasoconstriction is the hypothalamic hor-
mone arginine vasopressin (AVP). Apart from its role in osmoregulation it is an important sys-
temic vasoconstrictor by activating vascular V1-receptors in skin, skeletal muscle and the
splanchnic region [34] [35]. Studies revealed that dialysis patients exhibit higher AVP levels
than healthy individuals for reasons that are still under debate [33] [36] [37]. It has been
shown that AVP is important in maintaining hemodynamic stability during HD [38], and it
has been speculated whether an inadequate rise of AVP contributes to the development of
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intradialytic hypotension [37] [39] [40]. Furthermore, it has been shown that in the presence
of diabetic neuropathy, a condition where other neurohumoral pressor systems are compro-
mised, AVP becomes essential in maintaining blood pressure during circulatory stress [41]. All
these findings suggest that humoral factors are responsible for the altered vascular response of
the hepato-splanchnic region in diabetics compared to non-diabetic patients.
In critical care medicine, the ICG disappearance rate is frequently determined as a marker
of hepatic function and a surrogate of hepato-splanchnic blood flow based on its good clinical
applicability [42] [43]. In our study, however, the aforementioned discrepancies in hepato-
splanchnic perfusion could only be recognized by determining ICG clearance. There are
important differences with regard to the measurement and interpretation of ICG elimination.
For example, in the constant infusion approach the infusion rate (Qinf) to maintain a constant
ICG concentration (cb) in arterial or mixed venous blood is used to calculate clearance (K) as
the ratio of Qinf to cb (K = Qinf/cb). This, however, requires a constant plasma volume and a
steady state distribution of red blood cells [44] analyzed in a companion paper [45]. In the
bolus approach the elimination of ICG produces an exponential decline of ICG blood (or
plasma) concentrations. Log transformation of concentrations produces a linear decline, and
the rate constant (k, in 1/min) is determined by the slope of this line. The rate constant quanti-
fies the disappearance rate (in 1/min or %/min) and the half-life (in min), but it is insufficient
to quantify hepatic clearance (K) and hepato-splanchnic blood flow (Q) as the measurement of
clearance (K = kV) also requires quantitative information on the distribution volume (V).
Non-invasive devices used for measurement of ICG disappearance rate only report the elimina-
tion rate constant, which provides useful information on hepatic function, but fail to measure
hepatic clearance or hepato-splanchnic blood flow. This discrepancy is clearly seen in our data
where elimination rate remained almost unchanged without differences between diabetics and
non-diabetics (Tab. 2), but where hepato-splanchnic blood flow was lower in diabetics and sig-
nificantly decreased during HD and UF (Fig 2, bottom panel).
A limitation of our study is the relatively small number of patients which is not unusual for
this type of research [3, 4]. Moreover, all studies were repeated in subsequent midweek treat-
ments and showed a high reproducibility with negligible variation, indicating the validity of
our measurements. A further limitation is that we cannot provide information on the exact
fraction of cardiac output delivered to the hepato-splanchnic circulation received, and how this
fraction changed during ultrafiltration. Furthermore we did not take serial blood samples to
examine whether the decrease in hepato-splanchnic blood flow resulted in an increased risk for
bacterial translocation, endotoxemia and systemic inflammation. Therefore we cannot provide
evidence for a causal relationship between reduced hepato-splanchnic blood flow, intestinal
ischemia, and the occurrence of endotoxemia and systemic inflammation.
In conclusion, this study reveals that in chronic HD patients even a modest UF volume causes
a considerable increase in hepato-splanchnic vascular resistance due to active vasoconstriction,
especially in diabetics. To the best of our knowledge this is the first study to show that diabetic
HD patients exhibit a particularly high hepato-splanchnic resistance and a reduced hepato-
splanchnic blood flow. It can be speculated that diabetics therefore incur a higher risk for compli-
cations such as endotoxemia, systemic inflammation, and intradialytic hypotension. Further
studies are needed to provide direct evidence for a causal relationship between ultrafiltration
induced splanchnic ischemia and the occurrence of endotoxemia and systemic inflammation.
Supporting Information
S1 Table. Original data. Original data of individual measurements (n = 24) obtained in 12
subjects in two subsequent studies. Abbreviations: F: female;M: male; DM: diabetic; ND: non-
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diabetic; BMI: body mass index; BSA: body surface area; Vuf: ultrafiltration volume;MAP:
mean arterial pressure; HR: heart rate: Hct: hematocrit: Vp: plasma volume: QI: hepato-
splanchnic blood flow index: ICG-DR, Indocyanine green disappearance rate: RI, hepato-
splanchnic vascular resistance index; numbers behind variables refer to measuring times t.
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